Compare SPXC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPXC | PTGX |
|---|---|---|
| Founded | 1912 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.3B |
| IPO Year | 1994 | 2016 |
| Metric | SPXC | PTGX |
|---|---|---|
| Price | $179.70 | $143.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $245.56 | $108.23 |
| AVG Volume (30 Days) | 337.0K | ★ 454.6K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | ★ 2.73 | 2.35 |
| Revenue | ★ $2,265,100,000.00 | N/A |
| Revenue This Year | $16.07 | $874.25 |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $65.88 | ★ $61.50 |
| Revenue Growth | ★ 14.17 | N/A |
| 52 Week Low | $179.62 | $57.90 |
| 52 Week High | $251.08 | $160.81 |
| Indicator | SPXC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 32.75 | 47.68 |
| Support Level | N/A | $141.95 |
| Resistance Level | $225.70 | $160.81 |
| Average True Range (ATR) | 5.82 | 5.05 |
| MACD | -1.43 | -0.99 |
| Stochastic Oscillator | 12.29 | 34.46 |
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company operates through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The Detection and Measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others. It derives maximum revenue from United States.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.